Equity Overview
Price & Market Data
Price: $0.027
Daily Change: -$0.0056 / 20.74%
Range: $0.027 - $0.037
Market Cap: $2,037,484
Volume: 220,425
Performance Metrics
1 Week: 1.28%
1 Month: 5.78%
3 Months: -40.50%
6 Months: -28.31%
1 Year: -78.36%
YTD: -48.93%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.